subject: Aarkstore Enterprise - The Japanese Pharmaceutical Market 2008-2023 - Market Research Aggregator [print this page] The Japanese Pharmaceutical Market 2008-2023
Last year, the Japanese pharmaceutical market was the second largest in the world, with a value of $58.5bn. However, Japans market has experienced growth at a much lower rate than the other major pharmaceutical markets. It is at a key stage in its development. You need to take notice of these changes.
For many years the market has been dominated by the pricing and reimbursement policy of the Japanese government, which is arguably the most stringent of all the major governments. A determination to maintain tight cost controls on healthcare in Japan has resulted in the cost of drugs being tightly controlled. The government imposes limits on the price of drugs, and these are reduced every two years. This situation has caused concern to the international pharma industry, which remains eager to make further inroads into that large market. Are you achieving the success you should in Japan?
It is this imposed price control that is the key determining factor in influencing the shape, size and potential of the Japanese pharmaceutical market. The Japanese pharmaceutical market should have greater growth. However, the expansion of that market is influenced by several factors, including:
Biennial National Health Insurance drug price reductions
Increasing R&D expenses
Intensifying competition between domestic companies and foreign international pharmaceutical companies, especially market leaders
Restructuring within the pharmaceutical industry in Japan and worldwide
Non-availability of many leading international products
Relatively low use of generics
A regulatory system that has recently become more accessible to international pharma companies.
The Japanese pharmaceutical market is at the start of a cycle that will see an increasing number of mergers and overall consolidation. The extent of the mergers involving a global pharmaceutical company buying out a smaller Japanese company will depend largely on the pipeline of the Japanese company involved. Global pharmaceutical companies, such as Pfizer, are already establishing a major presence in Japan.
The Japanese Pharmaceutical Market 2008-2023 examines that leading market critically, through a comprehensive review of available information. Sources include in-depth interviews, primary research, industrial databases, commercial news, in-house reports and economic research. Visiongain also applied financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market report with detailed analysis and informed opinion. This information is not available anywhere else. In particular, this Japanese pharmaceutical market report from visiongain concentrates on the following essential aspects of that market:
Discussion of the current Japanese pharmaceutical market in the context of the global pharma market
Forecast of the overall Japanese pharmaceutical market from 2008 to 2023
Drivers and restraints facing the Japanese market
Opportunities and threats facing the Japanese market
Commercial prospects for the market-leading drugs, with sales forecasts from 2008 to 2023
Individual forecasts of the leading drug classes from 2008 to 2023
The potential of generics manufacturers to penetrate this market
Relevant pipeline developments with blockbuster potential
Currently marketed drugs with blockbuster potential
Discussion of unmet therapeutic needs
Why you should buy this report:
To receive a comprehensive analysis of the prospects for the Japanese pharmaceutical market from 2008 to 2023
To discover predicted revenues, growth rates and other key metrics for leading pharmaceutical treatments from 2008 to 2023, both by major therapeutic area and leading products
To determine prospects of leading companies in that market
To discover "hot" pipeline developments and up-and-coming products
To determine the forces that influence the Japanese market: drivers, restraints, strengths, weaknesses, opportunities and threats
To find out where the market is heading - both technologically and commercially from 2008 onwards
